GENB vs AVLN
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
GENB · Generate Biomedicines$9.54 ▼ 8.00%
AVLN · Avalyn Pharma$28.40 ▼ 1.05%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- GENB -24.5%
- AVLN -3.7%
Head to head
| Metric | GENB | AVLN |
|---|---|---|
| Price | $9.54 | $28.40 |
| Change today | ▼ 8.00% | ▼ 1.05% |
| Market cap | $1.23B | $1.26B |
| Return, 3 months | -46.2% | -24.6% |
| Return, year to date | – | – |
| Return, 1 year | – | – |
| P/E (TTM) | – | – |
| P/B | 3.2 | 3.4 |
| P/E percentile vs own 5y | 69th | 74th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -56.2% | – |
| Net profit growth (YoY) | -46.0% | -43.3% |
| Gross margin | – | – |
| Operating margin | -1,382.0% | – |
| Net margin | -1,381.8% | – |
| Return on equity | -76.4% | -25.9% |
| Analyst target vs. price | +172.5% | +111.3% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 33 | 51 |
| 30-day volatility | 107.6% | 62.3% |
| Max drawdown, 1 year | -53.2% | -40.6% |
| Trend read | Strong downtrend | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- AVLN is the largest of the group by market value.
- AVLN has been the calmest stock over the last 30 days.